Read More

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data In Support Of AV-101, A Novel Dry Powder Inhaled Formulation Of Imatinib, At The American Thoracic Society 2023 International Conference

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing   Formulation impacted lung exposure with dry powder demonstrating greater lung